Shilpa Lamba, MD
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,334 of the $2,102 with a category attached, or 63.5%. Teleflex LLC accounts for 63.2% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $1,203 and has fallen 81.3% since, to $225 in 2025.
Across 40 payments — averaging $52.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$1K
- Neotract Inc.$431
- Boston Scientific$133
- Urogen Pharma, Inc.$51
- Pfizer$44
- Tolmar, Inc.$28
- plus $87 from 4 others
What the payments were for
- Travel & lodging$1,33463%
- Food & beverage$72434%
- Education$442%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 16 | $1,328 |
| Neotract Inc. | 12 | $431 |
| Boston Scientific | 3 | $133 |
| Urogen Pharma, Inc. | 1 | $51 |
| Pfizer | 3 | $44 |
| Tolmar, Inc. | 1 | $28 |
| AbbVie | 1 | $28 |
| Medtronic | 1 | $23 |
| Accord Healthcare, Inc. | 1 | $22 |
| Axonics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$1,304
- Barrigel$129
- Moses 550 D\F\L$102
How this compares
$2,102 in reported general payments places this provider in the 70th percentile of 61 urology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 92 | $86,617 |
| GemtesaVibegron | 27 | $23,488 |
| Solifenacin Succinate | 66 | $7,798 |
| Estradiol | 103 | $7,743 |
| Tamsulosin Hcl | 418 | $5,529 |
| Potassium Citrate ErPotassium Citrate | 32 | $3,851 |
| Finasteride | 140 | $1,739 |
| Methenamine Hippurate | 35 | $1,735 |
| Cephalexin | 108 | $789 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 15 | $724 |
| Tolterodine Tartrate ErTolterodine Tartrate | 24 | $638 |
| Testosterone Cypionate | 23 | $530 |
| Oxybutynin Chloride | 47 | $418 |
| Testosterone | 11 | $411 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 43 | $255 |
Paid to pharmacies, not to this prescriber.
Other urology in Dover
- James BettiDover$2K
- Cormac OneillDover$2K
- Egbert BaumgartDover$1K
- Eric RaffinDover$522
- Sandy ChinDover$507
- Michael MichaelsDover$68
- Martin GrossKeene$172K
- Ramiro Madden-FuentesConcord$82K
- Jason AkermanManchester$53K
- Lori LernerLebanon$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.